abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

31 Dec 2004

Author:
AccountAbility & Business for Social Responsibility

[PDF] Business and Economic Development: Pharmaceutical Sector Report

[refers to Merck, Novo Nordisk, Aspen Pharmacare, Grunenthal, Novartis, Citadel Aurobindo Biotech & Citadel Fine Pharmaceuticals (both part of Aurobindo Pharmaceuticals), Abbott Laboratories, Bristol Myers-Squibb, Pfizer, Schering-Plough, Eli Lilly, Phytopharm, Ranbaxy Laboratories, Cipla, GlaxoSmithKine, Birzeit, AstraZeneca, Aventis, Boehringer Ingelheim, Forest Laboratories, Roche, Wyeth]

Timeline